Journalist
Hyeon Mi Cho
hmcho@ajunews.com
-
Korean Biopharma Ramps Up U.S. Production as Trump Tariff Uncertainty Grows February 23, 2026
-
Report: Nearly 80% of Biologics Losing EU Patents by 2032 Have No Biosimilar in Development February 22, 2026
-
South Korean Drugmakers Step Up FDA Filings to Enter U.S. Market February 8, 2026
-
Samsung Biologics Gets Third-Party Verification for Product Carbon Footprint System February 8, 2026
-
Celltrion tops 4 trillion won in annual sales, posts record operating profit February 5, 2026
-
PharmaResearch Annual Sales Top 500 Billion Won for First Time February 4, 2026
-
SK Bioscience Sales Jump 143% on Strong Results From German Unit IDT February 3, 2026
-
Turkey picks SK Plasma as partner in drive for domestic plasma-derived medicines November 25, 2025
-
Celltrion completes regulatory approvals for acquisition of Eli Lilly plant in US November 11, 2025
-
South Korea's Samsung Biologics hits record $4 billion in annual orders November 4, 2025
